Doliver Advisors LP Investment Activity Q3 2026: Key Purchases and Sales Observed
Doliver Advisors LP, as of September 30, 2026, managed a portfolio valued at approximately $454.8 million, showing significant buying activity in several stocks while reducing positions in others.
As of September 30, 2026, Doliver Advisors LP maintained a substantial portfolio valued at $454.76 million. The fund's holdings reflect a focus on major corporations and exchange-traded funds (ETFs), with significant changes observed in several positions during the most recent quarter.
The most pronounced change during Q3 2026 involved a substantial increase in holdings of several companies. Notably, CROWDSTRIKE HOLDINGS INC (CRWD) saw its position grow by 201.74% through share purchases, while IMMUNITYBIO INC (IBRX) and AMPHENOL CORP (APH) were both increased by 100%, indicating strong confidence in these investments. Additionally, positions in CRWD, IBRX, and CRBP were significantly boosted, although the specific percentage increases for CRBP and CRWD were not detailed in the filing.
Conversely, Doliver Advisors reduced exposure in certain sectors and specific holdings. The fund sold shares in SELECT SECTOR SPDR TR (XLV), a prominent ETF, reducing its position by 58.67% in terms of share count change. Similarly, holdings in STELLUS CAP INVT CORP (SCM) were drastically cut, with a 55.69% reduction in shares. Other notable decreases occurred in positions like ISHARES TR (IUSG) and ENTERPRISE PRODS PARTNERS L (EPD), although the percentage changes were less severe than the sales mentioned.
The overall portfolio allocation saw Energy as the largest sector, comprising 42% of the total value, followed by Technology at 12.47% and Communication Services at 4.32%. However, the data also included a category labeled 'Unknown' accounting for 20.94% of the portfolio value, which likely represents holdings where the sector information is not specified. Regarding disclosed activity in other sectors during this period, purchases in Real Estate and reductions in Healthcare (excluding the newly added positions) were not observed by Doliver Advisors.
The observed changes suggest a dynamic investment strategy focused on specific growth areas and selective reduction of exposure. The significant buying activity, particularly in CRWD, IBRX, and CRBP, points towards an interest in technology and healthcare sectors, specifically companies involved in cybersecurity and pharmaceuticals. The fund also demonstrated a continued interest in ETFs, albeit with a reduction in one significant holding.
In summary, Doliver Advisors' Q3 2026 filing highlights a pattern of targeted buying in specific tech and healthcare companies alongside the reduction of positions in certain ETFs and other sectors. For detailed analysis of their portfolio and investment history, readers can refer to the full report available on Doliver Advisors LP's page or explore individual holdings via the links provided for each stock.